多中心评估研究用NeuMoDx猴痘病毒全自动实时PCR检测
本研究在欧洲和美国三个站点评估了Qiagen研究用NeuMoDx猴痘病毒检测,分析灵敏度为50 copies/mL(分支I和II),临床验证对皮损拭子灵敏度99.21%(95%CI: 95.66-99.98%)、特异性96.64%(95%CI: 91.62-99.08%),显示可接受的分析与临床性能。
要点
- 该检测分析灵敏度为50 copies/mL,覆盖MPXV分支I和II。
- 临床验证灵敏度99.21%、特异性96.64%(皮损拭子)。
- 检测条可区分分支I和II,对实验室安全有重要意义。
核心结论
- NeuMoDx MPXV检测显示可接受的分析和临床性能,并能改善实验室工作流程。
- 检测条可区分MPXV分支I和II,具有重要实验室安全意义。
研究设计与样本
- 多中心评估研究,由欧洲和美国三个站点参与:约翰霍普金斯大学(美国)、根特大学医院(比利时)和圣塞西利奥大学医院(西班牙)。
- 共测试296份临床样本,并进行了计算机模拟特异性与包容性分析及分析灵敏度测试。
主要发现
- 分析灵敏度为50 copies/mL(分支I和II)。
- 计算机模拟显示分支I基因组80个中100%同源,分支II基因组5162个中99.98%同源。
- 分支II引物探针计算机模拟特异性100%;分支I的两组引物探针中至少有一组与天花、牛痘、骆驼痘和痘苗病毒存在同源性。
- 临床验证对皮损拭子灵敏度99.21%(95%CI: 95.66-99.98%),特异性96.64%(95%CI: 91.62-99.08%)。
临床怎么用
- 该检测整合核酸提取、PCR、数据分析和结果解读,可改善实验室工作流程。
- 检测可区分分支I和II,有助于排除受监管的分支I,满足临床实验室诊断需求。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: The mpox outbreak, caused by monkeypox virus (MPXV), accelerated the development of molecular diagnostics. In this study, we detail the evaluation of the Research Use Only (RUO) NeuMoDx MPXV assay by multiple European and US sites. The assay was designed and developed by Qiagen for the NeuMoDx Molecular Systems. Primers and probes were tested for specificity and inclusivity in silico. The analytical sensitivity of the assay was determined by testing dilutions of synthetic and genomic MPXV DNA. A total of 296 clinical samples were tested by three sites; the Johns Hopkins University (US), UZ Gent (Belgium, Europe), and Hospital Universitario San Cecilio (Spain, Europe). The analytical sensitivity of the assay was 50 copies/mL for both clades I and II. The assay showed 100% in silico identity for 80 clade I and 99.98% in silico identity for 5,162 clade II genomes. Clade II primers and probes showed 100% in silico specificity; however, identity of at least one of the two sets of clade I primers and probes with variola, cowpox, camelpox, and vaccinia viruses was noticed. The clinical validation showed sensitivity of 99.21% [95% confidence interval (CI): 95.66-99.98%] and specificity of 96.64% (95% CI: 91.62-99.08%) for lesion swab samples. The NeuMoDx MPXV Test shows acceptable analytical and clinical performance. The assay improves the laboratory's workflow as it consolidates nucleic acid extraction, PCR, data analysis, and interpretation and can be interfaced. The Test Strip can differentiate clades I and II, which has important laboratory safety implications. IMPORTANCE: In this manuscript, we provide detailed in silico analysis and clinical evaluation of the assay using a large cohort of clinical samples across three academic centers in Europe and the United States. Because the assay differentiates MPXV clades I and II, this manuscript is timely due to the current need to rule out the regulated clade I by diagnostic clinical laboratories. In December 2023, and due to first report of cases of sexually transmitted clade I infections in the Democratic Republic of the Congo, when generic assays that do not differentiate the clades are used, samples are considered regulated. The assay meets the need of full automation and has a marked positive impact on the laboratory workflow.
引用
- Mostafa HH, Wall G, Su S-C, et al. Multi-center evaluation of the Research Use Only NeuMoDx monkeypox virus (MPXV) fully automated real-time PCR assay. J Clin Microbiol. 2024. PMID: 38639489. doi:10.1128/jcm.00028-24
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。